Graziano F, Cascinu S, Staccioli M P, Catalano V, Rossi M C, Baldelli A M, Giordani P, Muretto P, Catalano G
Medical Oncology Unit, Hospital of Urbino, Italy.
BMC Cancer. 2001;1:9. doi: 10.1186/1471-2407-1-9. Epub 2001 Aug 1.
Loss of activity of tumor suppressor genes is considered a fundamental step in a genetic model of carcinogenesis. Altered expression of the p53 and the Deleted in Colon Cancer (DCC) proteins has been described in gastric cancer and this event may have a role in the development of the disease. According to this hypothesis, we investigated the p53 and the DCC proteins expression in different stages of gastric carcinomas.
An immunohistochemical analysis for detection of p53 and DCC proteins expression was performed in tumor tissue samples of patients with UICC stage I and II gastric cancer. For the purpose of the analysis, the staining results were related to the pathologic data and compared between stage categories.
Ninety-four cases of gastric cancer were analyzed. Disease stage categories were pT1N0 in 23 cases, pT2N0 in 20 cases, pT3N0 in 20 cases and pT1-3 with nodal involvement in 31 cases. Stage pT1-2N0 tumors maintained a positive DCC expression while it was abolished in pT3N0 tumors (p <.001). A significant higher proportion of patients with N2 nodal involvement showed DCC negative tumors. In muscular-invading tumors (pT2-3N0) the majority of cases showed p53 overexpression, whereas a significantly higher proportion of cases confined into the mucosa (pT1N0) showed p53 negative tumors. Also, a higher frequency of p53 overexpression was detected in cases with N1 and N2 metastatic lymph nodal involvement.
Altered expression of both DCC and p53 proteins is detectable in gastric carcinomas. It seems that loss of wild-type p53 gene function and consequent p53 overexpression may be involved in early stages of tumor progression while DCC abnormalities are a late event.
肿瘤抑制基因活性丧失被认为是致癌基因模型中的一个基本步骤。在胃癌中已描述了p53和结肠癌缺失(DCC)蛋白的表达改变,这一事件可能在疾病发展中起作用。根据这一假设,我们研究了p53和DCC蛋白在胃癌不同阶段的表达。
对国际抗癌联盟(UICC)I期和II期胃癌患者的肿瘤组织样本进行免疫组织化学分析,以检测p53和DCC蛋白的表达。为了进行分析,将染色结果与病理数据相关联,并在不同分期类别之间进行比较。
分析了94例胃癌病例。疾病分期类别为:23例为pT1N0,20例为pT2N0,20例为pT3N0,31例为有淋巴结受累的pT1 - 3。pT1 - 2N0期肿瘤维持DCC阳性表达,而在pT3N0期肿瘤中DCC表达消失(p <.001)。N2淋巴结受累患者中,DCC阴性肿瘤的比例显著更高。在肌层浸润性肿瘤(pT2 - 3N0)中,大多数病例显示p53过表达,而局限于黏膜层的病例(pT1N0)中,p53阴性肿瘤的比例显著更高。此外,在有N1和N2转移性淋巴结受累的病例中,检测到p53过表达的频率更高。
在胃癌中可检测到DCC和p53蛋白的表达改变。似乎野生型p53基因功能丧失及随之而来的p53过表达可能参与肿瘤进展的早期阶段,而DCC异常则是晚期事件。